Navigation Links
Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division

MISSISSAUGA, Ontario, BRIDGEWATER, New Jersey and BIRMINGHAM, Alabama, Jan. 10 /PRNewswire/ -- CANTOX HEALTH SCIENCES INC. and CANTOX US INC., a leading international scientific and regulatory consulting firm with specialized expertise in the areas of Pharmaceutical & Healthcare, Food & Nutrition, Chemicals and Agriculture, Biotech & Consumer Products announces the launch of Ashuren Health Sciences as the new name for their Pharmaceutical & Healthcare Division.

For the past 20 years, Cantox has been helping clients resolve complex scientific and toxicology issues, develop scientific and strategic regulatory plans, and facilitating timely regulatory global approvals. Cantox has been optimizing success and minimizing client risk through broad expertise and knowledge.

"The decision to rename the Pharmaceutical & Healthcare Division 'ASHUREN Health Sciences' was taken in order to more accurately represent our expanding global client base and to reflect our diverse international regulatory agency interactions," said Lindsay N. Donald, Vice President of Ashuren Pharmaceutical & Healthcare. "We have been assisting clients with their toxicology and drug development issues in Europe, North America, Asia and Australia."

"In order to rapidly and cost effectively move drugs through development it is imperative to anticipate scientific and regulatory issues ahead of time," commented Anna Metcalfe, Vice President of Regulatory Affairs for Ashuren. "This is where the experience of Ashuren's scientific and regulatory affairs consultants can really aid our pharmaceutical and biotech clients."

About Ashuren

Ashuren Health Sciences is a focused team of scientific and regulatory consultants that can help develop strategies, provide expert advice on all aspects of product development programs, and provide advice on a wide variety of toxicology and regulatory issues for pharmaceutical and related products. With diverse and in-depth experience in pharmaceutical development, our resourceful and innovative team consisting of board-certified toxicologists, regulatory affairs specialists and scientific writers address client's needs and accelerate their development programs. For more information, please visit:

SOURCE Ashuren Health Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... an additional independent director, and the Company welcomes ... allegations in a recent anonymous internet report on NW ... initiatives. Linda Powers stated, "We agree ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):